Weakened spindle checkpoint with reduced BubR1 expression in paclitaxel-resistant ovarian carcinoma cell line SKOV3-TR30

Gynecologic Oncology

Volumn 105, Issue 1, 2007, Pages 66-73

  Fu, Yunfeng ^a,b   Ye, Dafeng ^a,b   Chen, Huaizeng ^a,b   Lu, Weiguo ^a,b   Ye, Feng ^a,b   Xie, Xing ^a,b  

^a Womens Hospital   (China)

^b Women's Reproductive Health Laboratory of Zhejiang Province   (China)

Author keywords

BubR1; Drug resistance; Ovarian carcinoma; Paclitaxel; Spindle checkpoint

Indexed keywords

APC PROTEIN; BUB1 RELATED PROTEIN; CARBOPLATIN; CYCLIN B; DOCETAXEL; DOXORUBICIN; NOCODAZOLE; PACLITAXEL; PROTEIN MAD2; SECURIN; TOPOTECAN;

ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CARCINOMA CELL; CELL CYCLE ARREST; CELL CYCLE M PHASE; CELL CYCLE REGULATION; CENTROMERE; CHROMOSOME STRUCTURE; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; MITOSIS INDEX; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; SISTER CHROMATID;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CALCIUM-BINDING PROTEINS; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CHROMOSOME SEGREGATION; CYCLIN B; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MITOTIC SPINDLE APPARATUS; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; PACLITAXEL; PROTEIN KINASES; REPRESSOR PROTEINS; SISTER CHROMATID EXCHANGE;

EID: 33947324209     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2006.10.061     Document Type: Article

References (36)

1. Agarwal R., and Kaye S.B. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat. Rev. Cancer 3 (2003) 502-516
2. Jemal A., Murray T., Ward E., et al. Cancer statistics, 2005. CA Cancer J. Clin. 55 (2005) 10-30
3. Yusuf R.Z., Duan Z., Lamendola D.E., Penson R.T., and Seiden M.V. Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr. Cancer Drug Targets 3 (2003) 1-19
4. Huang Y., Ibrado A.M., Reed J.C., et al. Co-expression of several molecular mechanisms of multidrug resistance and their significance for paclitaxel cytotoxicity in human AML HL-60 cells. Leukemia 11 (1997) 253-257
5. Jang S.H., Wientjes M.G., and Au J.L. Kinetics of P-glycoprotein mediated efflux of paclitaxel. J. Pharmacol. Exp. Ther. 298 (2001) 1236-1242
6. Mozzetti S., Ferlini C., Concolino P., et al. Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin. Cancer Res. 11 (2005) 298-305
7. Gazitt Y., Rothenberg M.L., Hilsenbeck S.G., Fey V., Thomas C., and Montegomrey W. Bcl-2 overexpression is associated with resistance to paclitaxel, but not gemcitabine, in multiple myeloma cells. Int. J. Oncol. 13 (1998) 839-848
8. Liu J.R., Fletcher B., Page C., Hu C., Nunez G., and Baker V. Bcl-xL is expressed in ovarian carcinoma and modulates chemotherapy induced apoptosis. Gynecol. Oncol. 70 (1998) 398-403
9. Panvichian R., Orth K., Day M.L., Day K.C., Pilat M.J., and Pienta K.J. Paclitaxel-associated multimininucleation is permitted by the inhibition of caspase activation: a potential early step in drug resistance. Cancer Res. 58 (1998) 4667-4672
10. Jordan M.A., and Wilson L. Microtubules as a target for anticancer drugs. Nat. Rev. Cancer 4 (2004) 253-265
11. Abal M., Andreu J.M., and Barasoain I. Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action. Curr. Cancer Drug Targets 3 (2003) 193-203
12. Lopes C.S., and Sunkel C. The spindle checkpoint: from normal cell division to tumorigenesis. Arch. Med. Res. 34 (2003) 155-165
13. Bharadwaj R., and Yu H. The spindle checkpoint, aneuploidy, and cancer. Oncogene 23 (2004) 2016-2027
14. Weaver B.A.A., and Cleveland D.W. Decoding the links between mitosis, cancer, and chemotherapy: the mitotic checkpoint, adaptation, and cell death. Cancer Cell 8 (2005) 7-20
15. Kasai T., Iwanaga Y., Iha H., and Jeang K.T. Prevalent loss of mitotic spindle checkpoint in adult T-cell leukemia confers resistance to microtubule inhibitors. J. Biol. Chem. 277 (2002) 5187-5193
16. Anand S., Penrhyn-Lowe S., and Venkitaraman A.R. AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. Cancer Cell 3 (2003) 51-62
17. Masuda A., Maneo K., Nakagawa T., Saito H., and Takahashi T. Association between mitotic spindle checkpoint impairment and susceptibility to the induction of apoptosis by anti-microtubule agents in human lung cancers. Am. J. Pathol. 163 (2003) 1109-1116
18. Sudo T., Nitta M., Saya H., and Ueno N.T. Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint. Cancer Res. 64 (2004) 2502-2508
19. Dowling M., Voong K.R., Kim M., Keutmann M.K., Harris E., and Kao G.D. Mitotic spindle checkpoint inactivation by trichostatin A defines a mechanism for increasing cancer cell killing by microtubule-disrupting agents. Cancer Biol. Ther. 4 (2005) 197-206
20. Tao W., South V.J., Zhang Y., et al. Induction of apoptosis by an inhibitor of the mitotic kinesin KSP requires both activation of the spindle assembly checkpoint and mitotic slippage. Cancer Cell 8 (2005) 49-59
21. Kienitz A., Vogel C., Morales I., Muller R., and Bastians H. Partial downregulation of MAD1 causes spindle checkpoint inactivation and aneuploidy, but does not confer resistance towards taxol. Oncogene 24 (2005) 4301-4310
22. Swanton C., Tomlinson I., and Downward J. Chromosomal instability, colorectal cancer and taxane resistance. Cell Cycle 5 (2006) 818-823
23. Kops G.J., Foltz D.R., and Cleveland D.W. Lethality to human cancer cells through massive chromosome loss by inhibition of the mitotic checkpoint. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 8699-8704
24. Michel L., Diaz-Rodriguez E., Narayan G., Hernando E., Murty V.V., and Benezra R. Complete loss of the tumor suppressor MAD2 causes premature cyclin B degradation and mitotic failure in human somatic cells. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 4459-4464
25. Hauf S., Cole R.W., LaTerra S., et al. The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint. J. Cell Biol. 161 (2003) 281-294
26. Wang X.H., Jin D.Y., Ng R.W., et al. Significance of MAD2 expression to mitotic checkpoint control in ovarian cancer cells. Cancer Res. 62 (2002) 1662-1668
27. Nasmyth K. Segregating sister genomes: the molecular biology of chromosome separation. Science 297 (2002) 559-565
28. Wasch R., and Engelbert D. Anaphase-promoting complex-dependent proteolysis of cell cycle regulators and genomic instability of cancer cells. Oncogene 24 (2005) 1-10
29. Cahill D.P., Lengauer C., Yu J., et al. Mutations of mitotic checkpoint genes in human cancers. Nature 392 (1998) 300-303
30. Kim H.S., Park K.H., Kim S.A., et al. Frequent mutations of human Mad2, but not Bub1, in gastric cancers cause defective mitotic spindle checkpoint. Mutat. Res. 578 (2005) 187-201
31. Shichiri M., Yoshinaga K., Hisatomi H., Sugihara K., and Hirata Y. Genetic and epigenetic inactivation of mitotic checkpoint genes hBUB1 and hBUBR1 and their relationship to survival. Cancer Res. 62 (2002) 13-17
32. Chan G.K., Jablonski S.A., Sudakin V., Hittle J.C., and Yen T.J. Human BUBR1 is a mitotic checkpoint kinase that monitors CENP-E functions at kinetochores and binds the cyclosome/APC. J. Cell Biol. 146 (1999) 941-954
33. Chabalier C., Lamare C., Racca C., Privat M., Valette A., and Larminat F. BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance. Cell Cycle 5 (2006) 1001-1007
34. Fang Y., Liu T., Wang X., et al. BubR1 is involved in regulation of DNA damage responses. Oncogene 25 (2006) 3598-3605
35. Gorbsky G.J., Chen R.H., and Murray A.W. Microinjection of antibody to Mad2 protein into mammalian cells in mitosis induces premature anaphase. J. Cell Biol. 141 (1998) 1193-1205
36. Tang Z., Bharadwaj R., Li B., and Yu H. Mad2-independent inhibition of APCCdc20 by the mitotic checkpoint protein BubR1. Dev. Cell 1 (2001) 227-237